Status: Recruiting
A Study of Mirdametinib in People With Central Nervous System Tumors
The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Participants needed: 26
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Sep 3, 2026Locations: 7
Eligibility criteria
Cohorts A and B [+28]
Is pregnant or nursing [+13]